Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NYSE:ANVS NASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.68-2.1%$8.45$7.21▼$20.46$2.06B0.733.16 million shs2.14 million shsANIPANI Pharmaceuticals$80.82+0.3%$81.47$62.60▼$99.50$1.83B0.43306,324 shs361,342 shsANVSAnnovis Bio$1.81+5.6%$1.94$1.54▼$5.50$59.25M1.19937,082 shs465,253 shsMIRMMirum Pharmaceuticals$121.00+0.1%$107.45$50.25▼$130.00$7.37B0.481.04 million shs316,557 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-1.11%-3.69%+8.04%-16.71%-52.52%ANIPANI Pharmaceuticals-0.65%-6.33%-1.38%+5.32%+23.56%ANVSAnnovis Bio-2.29%-12.34%-5.54%-3.84%-40.49%MIRMMirum Pharmaceuticals+1.55%-5.78%+21.68%+25.40%+126.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.68-2.1%$8.45$7.21▼$20.46$2.06B0.733.16 million shs2.14 million shsANIPANI Pharmaceuticals$80.82+0.3%$81.47$62.60▼$99.50$1.83B0.43306,324 shs361,342 shsANVSAnnovis Bio$1.81+5.6%$1.94$1.54▼$5.50$59.25M1.19937,082 shs465,253 shsMIRMMirum Pharmaceuticals$121.00+0.1%$107.45$50.25▼$130.00$7.37B0.481.04 million shs316,557 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-1.11%-3.69%+8.04%-16.71%-52.52%ANIPANI Pharmaceuticals-0.65%-6.33%-1.38%+5.32%+23.56%ANVSAnnovis Bio-2.29%-12.34%-5.54%-3.84%-40.49%MIRMMirum Pharmaceuticals+1.55%-5.78%+21.68%+25.40%+126.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.50Moderate Buy$18.67115.05% UpsideANIPANI Pharmaceuticals 2.75Moderate Buy$107.3332.81% UpsideANVSAnnovis Bio 2.60Moderate Buy$11.67546.35% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$143.4018.51% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $17.007/10/2026ANIPANI Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$124.007/9/2026ANVSAnnovis Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$142.00 ➝ $148.007/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/6/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/6/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/2/2026MIRMMirum Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$115.00 ➝ $125.006/23/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/23/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.94$0.64 per share13.56$2.01 per share4.32ANIPANI Pharmaceuticals$883.37M2.08$9.97 per share8.11$24.03 per share3.36ANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/AMIRMMirum Pharmaceuticals$521.31M14.15$0.05 per share2,371.36$6.12 per share19.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.679.23N/A32.43%39.98%28.08%8/5/2026 (Estimated)ANIPANI Pharmaceuticals$78.34M$3.9520.469.33N/A9.98%27.51%10.02%8/14/2026 (Estimated)ANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/11/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A526.09N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)Latest ANIP, ADMA, ANVS, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ANVSAnnovis Bio-$0.44N/AN/AN/AN/AN/A8/5/2026Q2 2026ADMAADMA Biologics$0.16N/AN/AN/A$126.16 millionN/A7/30/2026Q2 2026MIRMMirum Pharmaceuticals-$0.7279N/AN/AN/A$166.03 millionN/A5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28$2.05+$0.77$1.28$207.63 million$237.46 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93ANIPANI Pharmaceuticals1.063.122.52ANVSAnnovis BioN/A1.271.27MIRMMirum Pharmaceuticals1.282.091.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%MIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%ANIPANI Pharmaceuticals8.10%ANVSAnnovis Bio20.80%MIRMMirum Pharmaceuticals8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableANIPANI Pharmaceuticals60022.75 million20.90 millionOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableANIP, ADMA, ANVS, and MIRM HeadlinesRecent News About These CompaniesHillsdale Investment Management Inc. Has $5.52 Million Stake in Mirum Pharmaceuticals, Inc. $MIRMJuly 15 at 5:43 AM | marketbeat.comMirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Emerald Advisers LLCJuly 14 at 4:23 AM | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from AnalystsJuly 13 at 4:13 AM | marketbeat.comCandriam S.C.A. Has $42.88 Million Position in Mirum Pharmaceuticals, Inc. $MIRMJuly 11, 2026 | marketbeat.comChristopher Peetz Sells 20,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockJuly 10, 2026 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 5,000 Shares of StockJuly 9, 2026 | insidertrades.comMirum Pharmaceuticals, Inc. $MIRM Shares Sold by SG Americas Securities LLCJuly 9, 2026 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 5,000 Shares of StockJuly 8, 2026 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells 20,000 Shares of StockJuly 8, 2026 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month High - What's Next?July 6, 2026 | marketbeat.comInsider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $326,520.00 in StockJuly 5, 2026 | americanbankingnews.comMirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its PortfolioJuly 4, 2026 | seekingalpha.comJolanda Howe Sells 2,721 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockJuly 3, 2026 | insidertrades.comSierra Summit Advisors LLC Takes $966,000 Position in Mirum Pharmaceuticals, Inc. $MIRMJuly 3, 2026 | marketbeat.comThe Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug ZilurgisertibJuly 2, 2026 | finance.yahoo.comMirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $125.00 at JPMorgan Chase & Co.July 2, 2026 | marketbeat.comMirum Pharmaceuticals, Inc. $MIRM Shares Sold by Pictet Asset Management Holding SAJuly 1, 2026 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Hits New 12-Month High - Time to Buy?June 30, 2026 | marketbeat.comAMI Asset Management Corp Purchases Shares of 8,859 Mirum Pharmaceuticals, Inc. $MIRMJune 30, 2026 | marketbeat.comStrength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?June 29, 2026 | zacks.comBiotech ETF Index Surges 10% After RebalanceJune 25, 2026 | etftrends.comENew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026ANIP, ADMA, ANVS, and MIRM Company DescriptionsADMA Biologics NASDAQ:ADMA$8.68 -0.19 (-2.14%) Closing price 04:00 PM EasternExtended Trading$8.72 +0.04 (+0.52%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$80.82 +0.27 (+0.34%) Closing price 04:00 PM EasternExtended Trading$80.87 +0.05 (+0.06%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$1.80 +0.10 (+5.56%) Closing price 03:59 PM EasternExtended Trading$1.80 -0.01 (-0.33%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Mirum Pharmaceuticals NASDAQ:MIRM$121.00 +0.11 (+0.09%) Closing price 04:00 PM EasternExtended Trading$121.00 0.00 (0.00%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
